Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience

Overview of attention for article published in The Journal of Headache and Pain, March 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

policy: 1 policy source

twitter: 10 X users

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 24 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

eptinezumab

Cited by Canadian Agency for Drugs and Technologies in Health on 18 Jan 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.